Conference reports

• Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK

• Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy

• When should HAART be started?

• MDR resistance transmission increases in the UK

• Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis

• Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)

• Clinical issues arising from a single treatment interruption

• A review of new anti-HIV drugs in development

• Antiretroviral therapy in children, women and intravenous drug users

• Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial

• Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients

• Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART

• Child protection issues around starting efavirenz in a mother on maintenance methadone

• Structured treatment interruptions

• Adherence and HAART: unique approaches to evaluating and improving adherence discussed

• Reports on lipodystrophy and metabolic complications

• Opportunistic infections in the HAART era

Antiretrovirals

• Importance of intensive adherence support for patients with HIV-related neurological symptoms

• Efavirenz side effects become long-term for over one in three

• ABT-378/r oral formulation available in UK

• Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor

Women's health

• Women initiate highly active antiretroviral therapy later than men

• Association of vitamin A deficiency With cervical squamous intraepithelial lesions in HIV-positive women

Side effects

• Adverse effects of antiretroviral therapy

Basic science and immunology

• Antiretrovirals do not independently affect T-cell count in HIV negative subjects

• Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells

• HLA-DR integrates with HIV-1 at chronic disease stage, may raise infectivity

Vaccines and microbicides

• Immune Response Corporation tried to block report on failure of Remune

Other news

• FDA meeting on approving immune therapies: background and comment

• HIV seroprevalence by anonymous testing in patients with mycobacterium tuberculosis and in tuberculosis contacts

• HIV-1 Immunogen fails to extend HIV progression-free survival

On the web

• AIDS-related lymphoma

PDFs

• Volume 1 Number 8 November / December 2000 PDF